

BAXTER INTERNATIONAL INC.
GAAP Key Product Line Sales
Periods Ending June 30, 2011 and 2010
(unaudited)
(\$ in millions)

	GAAP Q2 2011	GAAP Q2 2010	% Growth @ Actual Rates	% Growth @ Constant Rates	GAAP YTD 2011	GAAP YTD 2010	% Growth @ Actual Rates	% Growth @ Constant Rates
BioScience								
Recombinants	\$570	\$525	9%	3%	\$1,082	\$1,035	5%	2%
Plasma Proteins	363	314	16%	11%	671	606	11%	9%
Antibody Therapy	381	310	23%	21%	755	632	19%	19%
Regenerative Medicine	147	133	11%	6%	287	252	14%	12%
Other ¹	92	76	21%	12%	166	195	(15%)	(19%)
Total BioScience	\$1,553	\$1,358	14%	10%	\$2,961	\$2,720	9%	7%
Medical Products ²								
Renal	\$633	\$585	8%	2%	\$1,220	\$1,169	4%	0%
Global Injectables	506	472	7%	3%	1,023	923	11%	9%
IV Therapies	452	418	8%	3%	880	809	9%	6%
Infusion Systems ³	233	216	8%	5%	444	212	110%	106%
Anesthesia	143	130	10%	8%	261	257	2%	0%
Other	6	3	100%	25%	13	7	86%	20%
Total Medical Products ³	\$1,973	\$1,824	8%	3%	\$3,841	\$3,377	14%	11%
Transfusion Therapies ⁴	\$10	\$12	(17%)	(17%)	\$18	\$24	(25%)	(25%)
Total Baxter ³	\$3,536	\$3,194	11%	6%	\$6,820	\$6,121	11%	9%

¹ Principally includes vaccines and sales of plasma to third parties.

² Medical Products represents the combination of the company's former Medication Delivery and Renal businesses into a single global business unit. Effective January 1, 2011, the company changed its segment presentation to reflect this new structure, and recast all prior periods presented to conform to the new presentation.

³ GAAP net sales in the first quarter of 2010 included a charge of \$213 million related to the recall of COLLEAGUE infusion pumps. Refer to page 16 for a reconciliation to GAAP measures.

⁴ Represents revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the TT business after the February 2007 divestiture.